Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands

Virology

Volumn 280, Issue 2, 2001, Pages 253-261

  Ghezzi, Silvia ^a   Menzo, Stefano ^b   Brambilla, Andrea ^a   Bordignon, Paola Panina ^c   Lorini, Alessandro L ^a   Clementi, Massimo ^d   Poli, Guido ^a   Vicenzi, Elisa ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c ROCHE MILANO RICERCHE   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; LIGAND; RANTES;

ARTICLE; ASTROCYTE; BAY REGION BINDING SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; INHIBITION KINETICS; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; T LYMPHOCYTE; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0035866319     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0753     Document Type: Article

References (44)

1. The B-oligomer of pertussis toxin inhibits HIV-1 replication at multiple stages
2. The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains
3. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1
4. A new classification for HIV-1
5. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype
6. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry
7. V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1
8. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4
9. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
10. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells
11. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection
12. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals
13. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino acid substitution
14. Identification of a major co-receptor for primary isolates of HIV-1
15. Increased replication of T-cell-tropic HIV strains and CXC-chemokine receptor-4 induction in T cells treated with macrophage inflammatory protein (MIP)-1alpha, MIP-1beta and RANTES beta-chemokines
16. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
17. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
18. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule
19. Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo
20. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion
21. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia
22. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor
23. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization
24. Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates
25. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: Role of signal transduction
26. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay
27. Isolation and quantitation of HIV in peripheral blood
28. Coreceptor competition for association with CD4 may change the susceptibility of human cells to infection with T-tropic and macrophagetropic isolates of human immunodeficiency virus type 1
29. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha
30. Chemokine control of HIV-1 infection
31. Rare mutations in a domain crucial for V3-loop structure prevail in replicating HIV from long-term non-progressors
32. HIV-1 entry inhibitors: Evading the issue
33. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants
34. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1
35. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
36. In vivo evolution of HIV-1 coreceptor usage and sensitivity to chemokine-mediated suppression
37. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4
38. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene
39. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist
40. Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate
41. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a single transduction pathway that enhances viral infectivity
42. HIV-1 attachment: Another look
43. An integration defective U5 deletion mutant of HIV-1 reverts by eliminating additional LTR sequences
44. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure